ZYBT

6-K - Zhengye Biotechnology Holding Ltd (0001975641) (Filer)

Jilin, China, July 21, 2026 (GLOBE NEWSWIRE) -- Zhengye Biotechnology Holding Limited (NASDAQ:ZYBT) (the "Company" or "Zhengye"), a veterinary vaccine manufacturer that encompasses research, development, manufacturing, and sales of veterinary vaccines, with a focus on livestock vaccines in China, today issued the following statement in response to recent unusual trading activity in the price and trading volume of its Class A ordinary shares. The Company does not normally comment on market activity or rumors. However, in light of the magnitude of the recent trading activity in the Company's securities, the Company is providing the following statement. The Company confirms that it is not a

3 - Zhengye Biotechnology Holding Ltd (0001975641) (Issuer)

3 - Zhengye Biotechnology Holding Ltd (0001975641) (Issuer)

3 - Zhengye Biotechnology Holding Ltd (0001975641) (Issuer)

3 - Zhengye Biotechnology Holding Ltd (0001975641) (Issuer)

3 - Zhengye Biotechnology Holding Ltd (0001975641) (Issuer)

6-K - Zhengye Biotechnology Holding Ltd (0001975641) (Filer)

Jilin, China, June 04, 2026 (GLOBE NEWSWIRE) -- Zhengye Biotechnology Holding Limited (NASDAQ:ZYBT) (the "Company" or "Zhengye"), a veterinary vaccine manufacturer that encompasses research, development, manufacturing, and sales of veterinary vaccines, with a focus on livestock vaccines in China, announced that the Company had received a written notification letter (the "Notification Letter") from the Nasdaq Stock Market LLC ("Nasdaq") on May 29, 2026, notifying the Company that it is not in compliance with the minimum bid price requirement set forth in the Nasdaq Listing Rules 5550(a)(2) for continued listing on the Nasdaq. Nasdaq Listing Rule 5550(a)(2) requires listed securities to mai

20-F - Zhengye Biotechnology Holding Ltd (0001975641) (Filer)

JILIN, China, April 28, 2026 /PRNewswire/ -- Zhengye Biotechnology Holding Limited (NASDAQ:ZYBT) (the "Company" or "Zhengye"), a veterinary vaccine manufacturer that encompasses research, development, manufacturing, and sales of veterinary vaccines, with a focus on livestock vaccines in China, today announced its financial results for the fiscal year ended December 31, 2025. Mr. Songlin Song, co-chief executive officer of Zhengye, remarked, "Fiscal year 2025 was a year of resilience for Zhengye. While the broader hog market experienced low and volatile price fluctuations and government macro-control policies contributed to near-term pressure on swine vaccine demand, we remained focused on ex

3 - Zhengye Biotechnology Holding Ltd (0001975641) (Issuer)

3 - Zhengye Biotechnology Holding Ltd (0001975641) (Issuer)

Jilin, China, April 06, 2026 (GLOBE NEWSWIRE) -- Zhengye Biotechnology Holding Limited (NASDAQ:ZYBT) (the "Company" or "Zhengye"), a veterinary vaccine manufacturer that encompasses research, development, manufacturing, and sales of veterinary vaccines, with a focus on livestock vaccines in China, today announced the implementation of a dual-class share structure, effective April 7, 2026. At the annual general meeting of shareholders held on March 24, 2026, the Company's shareholders approved the introduction of two classes of ordinary shares, designated as Class A and Class B. The Company's Class A ordinary shares are expected to begin trading on the Nasdaq Capital Market at the open of

3 - Zhengye Biotechnology Holding Ltd (0001975641) (Issuer)

3 - Zhengye Biotechnology Holding Ltd (0001975641) (Issuer)

3 - Zhengye Biotechnology Holding Ltd (0001975641) (Issuer)

3 - Zhengye Biotechnology Holding Ltd (0001975641) (Issuer)

6-K - Zhengye Biotechnology Holding Ltd (0001975641) (Filer)

Jilin, China, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Zhengye Biotechnology Holding Limited (NASDAQ:ZYBT) (the "Company" or "Zhengye"), a veterinary vaccine manufacturer that encompasses research, development, manufacturing, and sales of veterinary vaccines, with a focus on livestock vaccines in China, today announced that Mr. Zhenfa Han, Chairman of the Board of Directors of Zhengye, has issued a letter to shareholders. In the letter, Mr. Han highlights the Company's research and operational milestones achieved in 2025 and outlines Zhengye's strategic priorities for growth in 2026. The full text of the letter follows. Dear Shareholders, As we enter 2026, on behalf of the management of Zhengye

6-K - Zhengye Biotechnology Holding Ltd (0001975641) (Filer)

JILIN, China, July 3, 2025 /PRNewswire/ -- Zhengye Biotechnology Holding Limited (Nasdaq: ZYBT) (the "Company" or "Zhengye"), a veterinary vaccine manufacturer that encompasses research, development, manufacturing, and sales of veterinary vaccines, with a focus on livestock vaccines in China, today announced its financial results for the fiscal year ended December 31, 2024. Mr. Songlin Song, co-chief executive officer of Zhengye, remarked, "Fiscal year 2024 was a transformational year for us, marked by strategic decisions and tough yet necessary shifts, as we navigated significant market adjustments and proactively diversified our customer base in pursuit of long-term growth. Amid global un

20-F - Zhengye Biotechnology Holding Ltd (0001975641) (Filer)

6-K - Zhengye Biotechnology Holding Ltd (0001975641) (Filer)

Jilin, China, May 23, 2025 (GLOBE NEWSWIRE) -- Zhengye Biotechnology Holding Limited (NASDAQ:ZYBT) (the "Company" or "Zhengye"), a veterinary vaccine manufacturer that encompasses research, development, manufacturing, and sales of veterinary vaccines, with a focus on livestock vaccines in China, today announced that it has received a letter from the NASDAQ Stock Market, dated May 20, 2025 (the "Delinquency Letter"), notifying the Company that it is not in compliance with the requirements for continued listing set forth in NASDAQ Listing Rule 5250(c)(1) because it did not timely file its annual report on Form 20-F for the fiscal year ended December 31, 2024 (the "2024 Annual Report"). In a